Jupiter Neurosciences (JUNS) Stock Price, News & Analysis

Company Overview

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.

Key Stats

• Today's Range: $1.77 to $2.74
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 1.73 million shs
• Average Volume: 556,345 shs
• Market Capitalization: $75.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Strong Buy

JUNS Stock Analysis - Frequently Asked Questions

How were Jupiter Neurosciences' earnings last quarter?

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) announced its quarterly earnings data on Thursday, May, 15th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by $0.02.

When did Jupiter Neurosciences IPO?

Jupiter Neurosciences (JUNS) raised $11 million in an initial public offering on Tuesday, December 3rd 2024. The company issued 2,800,000 shares at $4.00 per share. Dominari Securities and Revere Securities acted as the underwriters for the IPO.

When did the company's lock-up period expire?

Jupiter Neurosciences's lock-up period expired on Monday, June 2nd. Jupiter Neurosciences had issued 2,750,000 shares in its initial public offering on December 3rd. The total size of the offering was $11,000,000 based on an initial share price of $4.00. Since the expiration of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED-DRUGS
• Sub-Industry: N/A
• Current Symbol: NASDAQ:JUNS
• CIK: 1679628
• Web: www.jupiterorphan.com
• Phone: 561 406 6154
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.91
• Quick Ratio: 1.91

Sales & Book Value

• Annual Sales: $230 thousand
• Price / Sales: 329.56
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.13 per share
• Price / Book: 17.62

Miscellaneous

• Outstanding Shares: 33,100,000
• Free Float: N/A
• Market Cap: $75.80 million
• Optionable: Not Optionable
• Beta: N/A